HCV NEW INHIBITORS

HCV Progress in Therapy with Novel Sialomimetic-chimeric inhibitors

Coordinatore	UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO    more  Organization address address: DUOMO 6 city: VERCELLI postcode: 13100 contact info Titolo: Dr. Nome: Francesco Cognome: Cellerino Email: send email Telefono: +39 0321 660614
Nazionalità Coordinatore	Italy [IT]
Totale costo	1˙942˙500 €
EC contributo	1˙535˙000 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2012
Funding Scheme	BSG-SME
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2015-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO  Organization address address: DUOMO 6 city: VERCELLI postcode: 13100 contact info Titolo: Dr. Nome: Francesco Cognome: Cellerino Email: send email Telefono: +39 0321 660614	IT (VERCELLI)	coordinator	72˙500.00
2	CYATHUS EXQUIRERE PHARMAFORSCHUNGSGMBH  Organization address address: RUDOLFSPLATZ 2 1 8 city: WIEN postcode: 1010 contact info Titolo: Dr. Nome: Mario Cognome: Pinza Email: send email Telefono: 43124646326 Fax: 43124646666	AT (WIEN)	participant	485˙000.00
3	3S PHARMACOLOGICAL CONSULTATION & RES.SRL  Organization address address: STRADA SABINELOR 52 SECTORUL 5 city: BUCURESTI postcode: 50853 contact info Titolo: Dr. Nome: Loredana Georgiana Cognome: Manolache Email: send email Telefono: 40214112675 Fax: +4021 4110931	RO (BUCURESTI)	participant	482˙500.00
4	THERAPICON  Organization address address: VIA MALACHIA MARCHESI DE TADDEI 21 city: MILANO postcode: 20146 contact info Titolo: Prof. Nome: Paolo Alberto Cognome: Veronesi Email: send email Telefono: +39 02 433042 Fax: +39 02 48195224	IT (MILANO)	participant	443˙000.00
5	Aurigon Life Science GmbH  Organization address address: Bahnhofstrasse 9 - 15 city: Tutzing postcode: D-82327 contact info Titolo: Dr. Nome: Gundel Cognome: Hager Email: send email Telefono: +49 8158 259730	DE (Tutzing)	participant	13˙000.00
6	DUKE CHEM SA  Organization address address: AVINGUDA MARE DE DEU DE 99 city: OLERDOLA postcode: 8799 contact info Titolo: Mr. Nome: Joan Cognome: Amor Email: send email Telefono: 34938180186	ES (OLERDOLA)	participant	13˙000.00
7	INSTITUTULUL NATIONAL DE CERCETARE-DEZVOLTARE CHIMICO-FARMACEUTICA  Organization address address: CALEA VITAN 112 city: BUCURESTI postcode: 31299 contact info Titolo: Dr. Nome: Iuksel Cognome: Rasit Email: send email Telefono: 40213212117 Fax: 40213222917	RO (BUCURESTI)	participant	13˙000.00
8	PHARMA SERV INTERNATIONAL SRL  Organization address address: STRADA SABINELOR 52 SECTORUL 5 city: BUCURESTI postcode: 50853 contact info Titolo: Dr. Nome: Luigi Cognome: Silvestro Email: send email Telefono: 40214112675	RO (BUCURESTI)	participant	13˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV), which affects liver and is mainly transmitted by blood-to-blood contact. Infection is often asymptomatic, but when chronicized it causes liver inflammation (chronic hepatitis). This condition can progress to fibrosis, cirrhosis and cancer. Socio-economical quality of life is seriously affected by several aspects including domestic environment and workplace. Besides any ethical issue, the impact on the European and national health systems has a major relevance due to high costs of pharmacological treatments. At present, no vaccine against HCV is available. Standard therapy is currently based on double or triple combination (peginterferon, ribavirin and protease inhibitor), but it is ineffective to reduce symptoms in about 40% of cases, while clearance from viremia is not achievable. The market for HCV drugs is set to rapidly grow in the forthcoming years as new and more effective therapies will be available. Despite many scientific publications have envisaged during the most recent years the design and the study of new compounds targeting the glycans of the glycoproteins of the HCV envelope (gp120), no such kind of compounds have been described until now. Recent patent publications (WO2008/090151and WO2011/064303) have described innovative HCV inhibitors targeting such glycoproteins of HCV envelope. Some of those compounds have been already tested in typical in vitro assays eliciting a remarkable inhibitory activity on HCV. It remains to assess their effectiveness by implementing additional work packages. The current comprehensive proposal has been designed to develop the scientific and technological bases to assess most of the findings required to enter into clinical studies in humans with new HCV inhibiting compounds.'